Anxiety treatment innovations are rapidly changing the future of care in the United States, bringing fresh hope to people who have not responded to traditional medications or talk therapy. New research into psychedelic-based anxiety treatment innovations—like the LSD-derived compound MM120—shows that a single dose can significantly reduce generalized anxiety for weeks, with Phase 2 trial results strong enough to justify Phase 3 studies and potential FDA approval.
Besides psychedelics, other anxiety treatment innovations are emerging from technology. For instance, virtual reality exposure therapy enables people to face their fears such as flying, heights, or social situations in a controlled digital environment. Wearables that can detect subtle anxiety signals, such as skin conductance and eye movements, may be able to provide timely interventions, while app, based CBT and digital therapeutics continue to increase the availability of structured, evidence, based care.
According to experts, these anxiety treatment innovations will not substitute human clinicians but rather provide them with more tools to tailor the care and make high, quality support accessible to people who live far from clinics or have to deal with long waitlists.
Source: Compass Associates – Future Anxiety Treatment Research
Leave a Comment